OPINION

Reprogramming Bacteriophage Therapy with Artificial Intelligence: The Next Leap in AMR Combat

Neeraj Ranakoti, Khusboo Bisht, Deo Mani Tripathi
Department of Zoology, Pt. L. M.S. Campus Rishikesh, Sri Dev Suman Uttarakhand University

CORRESPONDING AUTHOR
Prof. Deo Mani Tripathi, Department of Zoology, Pt. L. M.S. Campus Rishikesh, Sri Dev Suman Uttarakhand University
Email: dmimmuno10@gmail.com

CITATION
Ranakoti N, Bisht K, Tripathi DM. Reprogramming Bacteriophage Therapy with Artificial Intelligence: The Next Leap in AMR Combat. Journal of the Epidemiology Foundation of India. 2026;4(1):128-130.
DOI: https://doi.org/10.56450/JEFI.2026.v4i01.016
ARTICLE CYCLE
Received: 27/05/2025; Accepted: 27/01/2026; Published: 31/03/2026
COPYRIGHT
© The Author(s), [2026]. Published by the Journal of the Epidemiology Foundation of India (JEFI) under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Antibiotics are extensively utilized as therapeutic agents, ranging from initial treatment to last-resort medications. Microorganisms have acquired antimicrobial resistance (AMR) as a result of their growing use and abuse. The ability of microorganisms, such as bacteria, fungi, viruses, and parasites, to withstand the effects of antimicrobial medications that were once efficient in treating infections is known as antimicrobial resistance (AMR). A major public health concern marked by higher treatment failures and mortality rates is caused by this phenomenon, which is made worse by variables including the overuse and inappropriate use of antibiotics. An estimated 700,000 fatalities worldwide are due to AMR each year (1) , a surge in resistant infections that is substantial, with resistance rates three to four times greater in low- and middle-income nations than in high-income ones (2).

India confronts major issues with AMR, with large economic expenditures connected with it, totalling to $2.5 billion yearly, according to an examination of AMR in five countries: the USA, India, China, the United Kingdom, and Pakistan(3). Additionally, according to the Global One Health Index (GOHI), Brazil and India exhibit significant shortcomings in their AMR laboratory networks and coordination capabilities, which worsens the AMR problem(4). According to estimations, bacterial AMR caused 4.95 million deaths globally in 2019, and by 2050, it might be the cause of 10 million deaths yearly(5). The crucial link between antimicrobial consumption and resistance is further highlighted by the WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), with India's high rates of antimicrobial consumption contributing significantly to the global AMR burden(6).

Effective treatment choices are made more difficult by the formation of resistant strains, which are caused by genetic changes and horizontal gene transfer. This results in higher rates of morbidity and mortality linked to drug-resistant illnesses(7). Additionally, the use of antiquated diagnostic methods makes it difficult to identify resistance in a timely and reliable manner, which leads to incorrect antibiotic use and exacerbates the issue(8). AMR has a significant financial impact; estimates suggest that it costs healthcare systems billions of dollars a year and increases hospital stays and medical expenses(9). Effectively combating AMR is further limited by the absence of strong surveillance and

antimicrobial stewardship programs, especially in environments with limited resources(10). Therefore, tackling these complex issues is essential to enhancing treatment results and preserving public health. Phage therapy's tailored approach against antibiotic-resistant bacteria is driving its revival as a tool to tackle antimicrobial resistance (AMR). Using bacteriophages—viruses that selectively infect and lyse bacterial cells—phage treatment provides a targeted substitute for conventional antibiotics without negatively impacting human or animal cells(11). This approach holds great promise for treating diseases such urinary tract infections brought on by resistant Escherichia coli strains, as phages can break down biofilms and work in concert with current antimicrobial therapies(12). Recent developments in phage immunobiology and clinical studies show that, despite regulatory obstacles, phage therapy has the ability to treat infections and alter the microbiome, thereby addressing the wider effects of AMR(13,14).

Phage therapy has considerable limits even though it is successful. One major issue is that bacteriophages only work on certain bacterial strains due to their limited host range, which makes phage cocktails necessary to increase their range of action(15). Furthermore, a significant obstacle is the possibility that bacteria would become resistant to phages since several antiphage defensive systems can reduce the effectiveness of phages(16). The therapeutic application of phage therapy is further complicated by regulatory and production issues, and uneven results are caused by a lack of standardized protocols regarding delivery methods, treatment duration, and phage titers(17). Furthermore, phage therapy's incorporation into standard medical practice is hampered by the lack of thorough pharmacokinetic data and applicable policies(15). Artificial intelligence (AI)-based phage therapy is a novel and promising approach as the global health community searches for workable solutions to the expanding problem of AMR.

AI-powered diagnostic tools are essential for detecting and describing bacterial strains that are amenable to phage therapy, which improves the efficacy of antimicrobial resistance (AMR) treatments. The previously time-consuming matching process can be greatly streamlined by these technologies, especially those that use machine learning (ML), which can analyze large datasets to anticipate phage-host interactions, evaluate phage susceptibility, and optimize phage cocktail formulations(18). For example, ML algorithms can speed up host range detection and phage resistance gene identification, both of which are necessary for customizing phage treatments for each patient(19). Furthermore, by overcoming the drawbacks of traditional optical tests, novel diagnostic techniques such as Phage-layer Interferometry (PLI) allow quantitative screening of phages in complicated media(20). Phage therapy can be tailored by incorporating these cutting-edge diagnostic tools, which will improve treatment results against bacterial illnesses that are resistant to antibiotics and tackle the urgent problem of antimicrobial resistance.

Declaration Of Generative AI And AI Assisted Technologies In The Writing Process

We hereby declare that there is no use of Artificial Intelligence (AI) tools in the writing, analysis, or preparation of this research paper. The work submitted is entirely original and prepared by the authors.

References

1. O'Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance; 2014. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
2. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance—the need for global solutions. The Lancet Infectious Diseases. 2013 Dec;13(12):1057-98. DOI: 10.1016/S1473-3099(13)70318-9.
3. Taylor J, Hafner M, Yerushalmi E, Smith R, Bellasio J, Vardavas R, et al. Estimating the economic costs of antimicrobial resistance. RAND Corporation; 2014. DOI: 10.7249/RR911.
4. Zhou N, Cheng Z, Zhang X, Lv C, Guo C, Global antimicrobial resistance: a system-wide comprehensive investigation using the Global One

Health Index. Infectious Diseases of Poverty. 2022;11(1):92. DOI: 10.1186/s40249-022-01016-5.
5. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb;399(10325):629-55. DOI: 10.1016/S0140-6736(21)02724-0.
6. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2021. Geneva: World Health Organization; 2021. Available from: https://www.who.int/publications/i/item/9789240027336
7. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews. 2010 Sep;74(3):417-33. DOI: 10.1128/MMBR.00016-10.
8. Okeke IN, Peeling RW, Goossens H, Auckenthaler R, Barell JK, Guerry P, et al. Diagnostics as essential tools for containing antibacterial resistance. Drug Resistance Updates. 2011 Dec;14(6):255-68. DOI: 10.1016/j.drup.2011.10.002.
9. World Bank. Drug-Resistant Infections: A Threat to Our Economic Future. Washington, DC: World Bank; 2017. DOI: 10.1596/26144.
10. Mendelson M, Matsoso MP. The World Health Organization Global Action Plan on Antimicrobial Resistance. South African Medical Journal. 2015;105(5):325. DOI: 10.7196/SAMJ.9644.
11. Gordillo Altamirano FL, Barr JJ. Phage Therapy in the Postantibiotic Era. Clinical Microbiology Reviews. 2019 Apr;32(2):e00066-18. DOI: 10.1128/CMR.00066-18.
12. Sybesma W, Zbinden R, Chanishvili N, Rodriguez-Coiradas M, Majas AM, Morales-Serna J, et al. Bacteriophages as Potential Treatment for Urinary Tract Infections. Frontiers in Microbiology. 2016;7:465. DOI: 10.3389/fmicb.2016.00465.
13. Roach DR, Leung CY, Henry M, Morello E, Singh S, Di Santo JP, et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host & Microbe. 2017 Jul;22(1):38-47.e4. DOI: 10.1016/j.chom.2017.06.018.
14. Febvre HP, Rao S, Abdallah M, Pyter AJ, Coleman RJ, Abdo Z, et al. PHAGE Study: Effects of Supplemental Bacteriophage Intake on Inflammation and Colon Microbiota in Healthy Adults. Nutrients. 2019 Mar;11(3):666. DOI: 10.3390/nu11030666.
15. Ross A, Ward S, Hyman P. More is Better: Selecting for Broad Host Range Bacteriophages. Frontiers in Microbiology. 2016;7:1352. DOI: 10.3389/fmicb.2016.01352.
16. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nature Reviews Microbiology. 2010 May;8(5):317-27. DOI: 10.1038/nrmicro2315.
17. Fauconnier A, Josse J, Debarbieux L, Cena-Diez R, Pirnay JP, Verbeken G, et al. Phage Therapy: Regulatory Issues and Challenges. Frontiers in Microbiology. 2020;11:584068. DOI: 10.3389/fmicb.2020.584068.
18. Doud MB, Robertson JM, Strathdee SA. Optimizing phage therapy with artificial intelligence: a perspective. Frontiers in Cellular and Infection Microbiology. 2023;13:1200216. DOI: 10.3389/fcimb.2023.1200216.
19. Boeckaerts D, Stock M, Criel B, Gerstmans H, De Baets B, Briers Y. Predicting bacteriophage hosts based on sequences of receptor-binding proteins. Briefings in Bioinformatics. 2021 Sep;22(5):bbab085. DOI: 10.1093/bib/bbab085.
20. Zheng Y, Zhang Y, Zheng Y, Zhao Y, Zhang Y. Quantitative screening of phages in complicated media using phage-layer interferometry. Sensors and Actuators B: Chemical. 2021 Oct;343:130149. DOI: 10.1016/j.snb.2021.130149.